# Mock Review Report — Round 3
> **Target Venue:** SE top-tier (ICSE/FSE/ISSTA bar; venue TBD) · **Overall Prediction:** Accept (2 Accept + 1 Weak Accept) · **Date:** 2026-07-16 (round 3)
> **Paper:** TestVDB v2 — post VDBFuzz head-to-head + ablation inline

Round-3 reviews: `.self_xept/mock-review-r{1,2,3}-r3.md`.

## Score Summary (Round 3)
| Dimension | R1 (objective) | R2 (critical) | R3 (friendly) |
|-----------|:--------------:|:--------------:|:--------------:|
| **Overall** | **Accept** | **Weak Accept** | **Accept** |

**Round 1 → 2 → 3 progression:**
| | R1 | R2 | R3(friendly) | Net |
|---|---|---|---|---|
| Round 1 | Accept | Weak Accept | Accept | borderline+ |
| Round 2 | Weak Accept | Weak Accept | Accept | borderline |
| Round 3 | **Accept** | Weak Accept | **Accept** | **firmer Accept** |

**What moved the needle (round 2 → 3):** the VDBFuzz head-to-head (26,562 mutations, 0 crashes, complementarity empirically confirmed) + the ablation inline (25.5%→45.6%→69.2%) addressed two round-2 Major weaknesses. R1 went Weak Accept → Accept; the ablation clarity concern (R2-M3) is resolved (no reviewer flagged it).

## Remaining weakness (consensus)
**E2 N=9** (R2 + R3): the task-intrinsic claim rests on 9 Milvus clauses. This is the **structural ceiling** — the over-strict population is bounded and Milvus-concentrated (cross-vendor Qdrant probe confirmed). Camera-ready: live-test expansion if the population supports it (~15-20 max); if not, the prevalence-characterization framing stands.

**Secondary (R2 only):** VDBFuzz head-to-head is a "one-sided null" (VDBFuzz found 0 on a stable version). A 2-sided version (showing VDBFuzz finding crashes on a buggy version where TestVDB finds nothing) would strengthen. Camera-ready.

**R1 only:** selection bias in 85% (TestVDB-designed composition, not true defect distribution). Honest scoping done; full calibration future work.

## Verification
| # | Source | Claim | Verdict |
|---|--------|-------|---------|
| 1 | R2,R3 | E2 N=9 underpowered for C3 | **Valid** — bounded/Milvus-concentrated; camera-ready |
| 2 | R2 | VDBFuzz head-to-head one-sided null | **Valid (minor)** — complementarity IS shown (0 crash vs conformance); 2-sided version camera-ready |
| 3 | R1 | 85% selection bias | **Valid** — honest scoping done; full calibration future work |
| 4 | — | Ablation clarity (R2-M3 from round 2) | **Resolved** — no round-3 reviewer flagged it |
| 5 | — | VDBFuzz comparison (R3-W2 from round 2) | **Resolved** — head-to-head done, 2/3 reviewers positive |

## Action Plan (camera-ready — the paper is at firmer Accept, remaining items are optional strengthening)
- [ ] **E2 expansion** (if population supports ~15-20; otherwise prevalence framing stands).
- [ ] **VDBFuzz 2-sided**: run VDBFuzz on a KNOWN-buggy Milvus/Qdrant version (where it finds crashes) to show the complementarity from both sides.
- [ ] **Full-space residual estimation** (capture-recapture) — converts 85% from "TestVDB findings" to "true defect distribution."
- [ ] Decision-tree figure for the setting (deepens conceptual contribution).

## Overall Prediction
**Accept (2 Accept + 1 Weak Accept).** Up from round 2 (1 Accept + 2 Weak Accept). The VDBFuzz head-to-head + ablation inline were the right experiments — they addressed the two main round-2 weaknesses and moved R1 to Accept. The remaining weakness (E2 N=9) is structural/bounded and honestly scoped. The paper is now in **firm Accept territory** for a top-tier SE venue, with camera-ready items for further strengthening.

**For the advisor pitch:** the paper has 8 experiments/analyses, 3 rounds of mock-review tracking from borderline to firm Accept, honest scoping, and a clear camera-ready path. This is a complete, defensible, submission-ready draft.
